Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy. Interim blinded data from a Phase 1 study in healthy trial participants demonstrated that single doses of GS-6207 of up to 450 mg, administered subcutaneously, achieved sustained concentration levels and were well-tolerated. Separately, in vitro data demonstrated picomolar potency with GS-6207, including against HIV strains resistant to other antiretroviral (ARV) classes. The data were presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle (Session O-06).
“These studies indicate that GS-6207, a first-in-class, investigational capsid inhibitor, may represent a novel approach to HIV treatment due to its long-acting characteristics and potent antiviral activity seen in vitro,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The data presented at CROI support advancing GS-6207 to the next phase of clinical trials to gain a deeper understanding of its potential role as a long-acting agent for people living with HIV.”
GS-6207 was evaluated in 40 healthy trial participants in an ongoing Phase 1 randomized, blinded, placebo-controlled, safety, tolerability and PK study. The participants were randomized (4:1) in four staggered single dose escalation cohorts to receive GS-6207 (n=8/cohort) or placebo (n=2/cohort), at 30, 100, 300 or 450 mg. Through 20 weeks (30 mg cohort) to 4 weeks (450 mg cohort) of study, there were no deaths, serious adverse events (AEs) or Grade 3 or 4 AEs. Most AEs were mild (Grade 1) and resolved. PK parameters for the 30 mg and 100 mg cohorts have been estimated; analyses for the 300 mg and 450 mg cohorts are ongoing. The PK profile of subcutaneously administered GS-6207 is consistent with sustained delivery, supporting a dosing interval of at least 3 months at doses greater than 100mg.
The in vitro study evaluated the pharmacological profile of GS-6207 – which demonstrated up to >100-fold greater potency than certain commonly prescribed ARVs and synergistic antiviral activity when combined with the ARVs tenofovir alafenamide, efavirenz, dolutegravir or darunavir. The in vitro study also demonstrated that GS-6207 retains full potency against a broad range of HIV-1 strains resistant to other ARV classes.
Gilead has initiated a Phase 1b study of GS-6207 in people living with HIV.
GS-6207 is an investigational therapy and not approved by any regulatory body globally; its safety and efficacy have not been established. There is no cure for HIV or AIDS.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 11.5 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. In addition, we may have difficulties conducting the Phase 1b clinical study of GS-6207 as currently anticipated. In addition, we may observe unfavorable results from additional studies GS-6207 and Gilead may make a strategic decision to discontinue development of GS-6207 if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, GS-6207 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter ( @GileadSciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Ryan McKeel, Media
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Algorand Foundation Marks New Chapter in Global Economics with Inaugural Auction19.6.2019 23:56:00 EEST | Tiedote
The Algorand Foundation announced today the successful completion of its inaugural Algo auction, marking the launch of the Algorand platform and its original economic model that uses a unique combination of consensus-driven blockchain technology and economic incentives to ensure absolute fairness and broad participation in a new Borderless Economy. The auction brings Algos, the native token of the Algorand blockchain platform, into market circulation for the first time. Originally scheduled to last for more than five hours, the auction sold out in under four hours, due to oversubscribed demand from a large group of global participants. The Dutch Auction mechanism ensured the market, not the seller, set the price of the offering and that each participant paid the same price per Algo. The Algorand platform is the first public, permissionless pure proof-of-stake blockchain protocol that solves the “blockchain trilemma” of achieving scalability, security and true decentralization all at on
Cooper & Turner Announces Potential Combination with Beck Industries19.6.2019 22:32:00 EEST | Tiedote
Andaray (Holdings) Limited and its direct and indirect subsidiaries (“Cooper & Turner”) have entered into an agreement with Beck Industries (“Beck”) for potential combination of the two groups. The contemplated combined entity aims to be the first truly global manufacturer of safety critical fasteners, together supporting a broader range of industries – including renewable energy, tunneling, construction, rail, heavy equipment, downstream oil & gas, power generation and nuclear, among others. Headquartered in Sheffield, England, Cooper & Turner serves a global customer base with manufacturing and distribution operations across the European Union, China and North America. This worldwide network enables Cooper & Turner to offer a seamless, one-stop shop solution for industrial fasteners that meet the highest levels of quality. Beck, a France-based manufacturer and distributor of fully certified, high-security bolting components, has built a global operation that complements and expands t
Tinubu Square Appoints Sophie Riottot as Group Sales Director19.6.2019 20:02:00 EEST | Tiedote
Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, has announced the appointment of Sophie Riottot as Group Sales Director. This is a strategic engagement for the company, which is restructuring its sales approach to reinforce its rapid global growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005634/en/ Sophie Riottot, new Group Sales Director at Tinubu Square (Photo: Business Wire) Sophie Riottot brings a wealth of experience to Tinubu Square. She joins the company from Dhatim, a French start-up specializing in AI-powered invoice services, where she was responsible for sales strategy and partnership development. Prior to this, she was with Microsoft for over 17 years, in a variety of prominent sales and management positions, including Head of Finance in the Services Division. As a member of the executive committee at Tinubu Square, Sophie will be responsible for spearheadin
ExaGrid Voted “Enterprise Backup Hardware Product of the Year”19.6.2019 20:00:00 EEST | Tiedote
ExaGrid®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been voted Storage Magazine’s “Enterprise Backup Hardware Product of the Year” at its annual awards ceremony Storries XVI. Winners are determined by public vote, so receipt of this award is especially important; it heralds the collective voices of ExaGrid’s customers and partners, and further validates the excellence of ExaGrid’s differentiated product architecture and superior customer support model. “We’re honored to accept this award from Storage Magazine,” said Bill Andrews, President and CEO of ExaGrid. “ExaGrid’s deduplication and its scale-out architecture provides customers with a consistent backup window regardless of data growth, which is especially important in today’s ever-changing enterprise environments. The scale-out approach also eliminates forklift upgrades and forced product obsolescence. Our unique Landing Zone retains the most recent backup in its full undedupl
Luxury Pre-War Elevator Building in Prestigious Brooklyn Heights Offered for Sale19.6.2019 19:12:00 EEST | Tiedote
Holliday Fenoglio Fowler, L.P. (HFF) announces it has been selected to exclusively market the sale of 25 Monroe Place, a 12-story, 67-unit, luxury apartment building located in the Brooklyn Heights neighborhood of Brooklyn, New York. This offering provides a rare opportunity to acquire a trophy asset in the most sought-after neighborhood in Brooklyn. The vast majority of the property is comprised of fair-market units not subject to rent stabilization. 25 Monroe Place is situated in the Brooklyn Heights historic district, which provides immediate access to Manhattan, the Brooklyn Waterfront, Brooklyn Bridge Park, Downtown Brooklyn and DUMBO. Brooklyn Heights is characterized by charming brownstones and plush tree-lined streets, and the property is surrounded by medium- and low-density buildings that provide water and Manhattan skyline views. Built in 1938, 25 Monroe Place combines pre-war architectural elements and spacious apartment layouts with newly upgraded condo-quality finishes, i
Shopify Unveils New Innovations to Transform Commerce for Merchants and Consumers Globally19.6.2019 18:30:00 EEST | Tiedote
Today, Shopify Inc. (NYSE:SHOP) (TSX:SHOP), the leading multi-channel commerce platform, unveiled the latest in commerce technology at Shopify Unite, the annual conference that brings together the company’s global partner and developer community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005550/en/ Shopify Fulfillment Network (Graphic: Business Wire) “Shopify’s real power comes from the variety and strength of our ecosystem,” said Shopify CEO Tobi Lutke. "Unite gives our developer and partner community access to our product roadmap. Together, and only together, we can shape the future of commerce and empower entrepreneurs around the world.” This year, Shopify is transforming commerce by announcing platform enhancements and updates focused on giving direct-to-consumer brands everything they need to build and manage a business. Shopify’s innovations include a newly updated Shopify Plus platform for enterprise brands
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme